In particular, compared to the Ctrl group, CD8+IFNγ+ T cells were significantly higher in the IASNDS@gel treatment group, suggesting a more pronounced anti-tumor immune response within the GBM (Supplementary Fig. 22). The gene discussed is CD8A; the disease is glioblastoma.